Biomarker Discovery

The identification of diagnostic and prognostic biomarkers and their translation to the clinic is crucial in the development of new therapeutic drugs.

We can support biomarker discovery, companion diagnostics and assay development by providing access to rare diseases and highly annotated samples from specific patient genotypes, disease stage or specific medications. Samples are available with expression information such as ER/PR/Her2 scoring or PSA data. Matched blood samples and follow-up information can also be provided.

We also offer access to an extensive population biobank, primary isolated cells, useful in assay development and the identification of diagnostic and prognostic markers. Repeat donor collections for longitudinal studies can also be provided.

  • Fresh Tissues (Link to fresh tissue product page)
  • Biofluids (Link to biofluids product page)
  • Primary Cells and Cell Lines (Link to cell products product page)

As well as offering samples we can support immunocytochemistry staining and scoring and/or quantification of IHCISH and IF marker staining within cells and tissues using image analysis.

IND submissions

The FDA recommends the inclusion of full tissue cross—reactivity data for successful therapeutic antibody IND submissions. We supply all of the high-quality normal tissues required for both the FDA and EMEA tissue panels. All samples are ethically obtained with full donor or donor family consent, from post-mortem or surgical sources as required.

Our fully GLP and GCP compliant laboratory can undertake TCR studies, in human and animal tissues. All TCR studies are run to the FDA guidelines. The reporting of the stained tissues is undertaken by a pathologist. A full report is issued covering the IHC optimisation of the test antibody, tabulated results (identifying any positive binding cell, binding intensity and frequency of binding), conclusions and any appropriate images.

In addition to the TCR study we often run studies to identify lead candidates before committing to the main TCR study. This can be in the form of a limited number of tissues or using a TMA.

We’re here to help

Talk to one of our team members and find out more.

We can help in all areas of your drug discovery and development